Production and Characterization of High-Titer Stocks of Rev-Defective HIV-1  by RIGGS, NANETTE L. & GUATELLI, JOHN C.
VIROLOGY 217, 602–606 (1996)
ARTICLE NO. 0156
SHORT COMMUNICATION
Production and Characterization of High-Titer Stocks of Rev-Defective HIV-1
NANETTE L. RIGGS*,† and JOHN C. GUATELLI*,†,1
*The San Diego Veterans Affairs Medical Center and the †Department of Medicine, University of California at San Diego,
9500 Gilman Drive, La Jolla, California 92093-0679
Received October 20, 1995; accepted January 25, 1996
High-titer stocks of rev-defective HIV-1 virions have been produced and characterized. To produce these stocks, CEM
cells transduced with a murine retroviral vector that expresses Rev were used to support the growth of an HIV-1 genome
containing four inactivating mutations in the rev gene. The resulting viral stocks were of high-titer when used to infect CEM
cells that expressed Rev, but had no measurable titer when used to infect parental CEM cells; replication-competent virus
was not detected. As expected, these rev-defective viruses established early gene expression in parental CEM cells as
demonstrated by the accumulation of viral mRNAs and Nef protein. The expression of late genes was impaired as demon-
strated by the inability of these viruses to direct the accumulation of singly spliced mRNA or p24 antigen. These defective
viruses did not interfere with replication of the wild-type virus, although they were produced at low levels during coinfection
experiments. This experimental system may be useful for the study of early events during the HIV-1 life cycle. In addition,
this system represents a simple method of gene transfer into CD4-positive cells using replication-defective but transcription-
ally active HIV-1. q 1996 Academic Press, Inc.
The ability to produce high-titer stocks of replication- In the present study, high-titer stocks of rev-defective
defective HIV-1 has several potential applications. Genet- HIV-1 have been produced and characterized. To pro-
ically characterized viruses encoding specific defects duce these viral stocks, an HIV-1 genome was con-
would allow analysis of the interaction of replication- structed that contains four inactivating mutations within
defective with replication-competent viruses in vitro. rev: the initiator codon was changed from ATG to ACG;
These viruses might also be used as vectors for gene codon 49 was changed from CAG to TAG; codon 51 was
transfer into CD4-positive cells, delivering antiviral genes changed from CAG to TAG; and codon 54 was changed
or expressing immunogenic viral gene products. from TCG to TAG. These mutations in both the first and
A conceptually simple approach to the production of second coding exons of rev were introduced sequentially
replication-defective HIV stocks is trans-complementa- into the 2.8-kb EcoRI/BamHI fragment of the plasmid
tion of genomes that are defective in essential, early pNL43 using oligonucleotide-directed mutagenesis as
regulatory genes. These genes are tat, which encodes described previously (4). After verification of the nucleo-
a transcriptional activator of the viral LTR and rev, which tide sequence, the mutated fragment was inserted into
encodes a posttranscriptional activator of structural gene pNL43 to create the plasmid pRS4X.
expression (1). One such system has been constructed To propagate this rev-defective genome as virus, a
previously in which a virus containing defects in both tat T lymphoid cell line that expresses Rev constitutively
and rev can be grown in cells that express both Tat was obtained using transduction with a murine retrovi-
and Rev from a bicistronic cDNA (CEMTART) (2). Stocks ral vector. The retroviral vector LRevSN expresses Rev
of defective virus obtained from this culture system were from a cDNA sequence under the control of the MuLV
free of replication competent virus. The lack of reconstitu- LTR and the selectable marker neoR under the control
tion of wild-type virus by recombination may have been of an SV40 promotor (5). PA317 cells producing this
due to the introduction of inactivating point mutations in vector were provided by Ingrid Bahner and Donald
both the first and second coding exons of the tat and rev Kohn (Childrens Hospital Los Angeles, University of
genes of the defective virus. These coding exons are Southern California School of Medicine). Supernatant
separated by an intron of 3 kb contained in the genomic from a culture of the vector-producing cells was used
RNA (3). to transduce CEM cells. After initial selection in G418
at 800 mg/ml, the cells were cloned by limiting dilution.
A clone (designated CEMrev1) was identified that ex-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (619) 552-7445. pressed rev-RNA as detected using cDNA-PCR (data
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CEMrev1 cells as targets. The titrations were performed
using serial 10-fold dilutions of the viral stocks to infect
5 1 104 cells in quadruplicate as described previously
(6). The microcultures were evaluated for cytopathic ef-
fect after 2 weeks, and the 50% tissue culture infectious
dose (TCID50) was calculated as described (6). These
titrations revealed that the rev-defective RS4X virus had
no detectable titer on CEM cells but had titers of greater
than 105 TCID50/ml on CEMrev1 cells (Table 1). The titers
of wild-type virus measured using CEM or CEMrev1 cells
as targets were similar (Table 1). This similarity allowed
the nominal titer of the defective RS4X virus on parental
CEM cells to be inferred from the measured titer on CEM-
rev1 cells.
To investigate the impact of nef on the infectivity of
the rev-defective vector RS4X, a nef-defective variant of
the RS4X genome was constructed by exchanging the
EcoRI–BamHI fragment of pRS4X (containing the four
mutations in rev) with that of the plasmid pAS, a mutant
of pNL43 in which the Nef initiator codon has been abol-
ished (ATG changed to CTG) using overlap PCR as de-
scribed previously (6). The resulting plasmid, pRSNS, de-
fective in both rev and nef, was used to transfect tran-
siently CEMrev1 cells and virus was propagated to
concentrations of p24 antigen greater than 1 mg/ml (Ta-
ble 1). The titer of this viral stock as determined in CEM-
rev1 cells was greater than 104 TCID50/ml (Table 1).
FIG. 1. (A) Growth curves of HIV-1 genomes following transfection Again, this rev-defective viral stock had no detectable
of CEM cells (106) or CEMrev1 cells (106) with 1 mg of proviral plasmid
titer when CEM cells were used as targets. The ratio ofDNA using cationic liposomes. Open circles, NL43 (wild-type) in CEM
p24 antigen to TCID50 for the rev- and nef-defective RSNScells; open squares, RS4X (rev-defective) in CEM cells; closed circles,
virus stock was 20-fold greater than that of the RS4XNL43 in CEMrev1 cells; closed squares, RS4X in CEMrev1 cells. (B)
Growth curves of viruses (produced originally from CEMrev1 cells) virus which contains an open nef reading frame. This
following infection of parental CEM cells or CEMrev1 cells at an m.o.i. observation is consistent with the requirement of nef for
of 0.15 (1.5 1 105 TCID50/106 cells). Open circles, NL43 in CEM cells; optimal viral infectivity (6).open squares, RS4X in CEM cells; closed circles, NL43 in CEMrev1
The ability of the rev-defective RS4X virus to initiatecells; closed squares, RS4X in CEMrev1 cells.
viral transcription in parental CEM cells was tested using
a cDNA-PCR assay for spliced mRNAs (4, 7). Cells (106)
were exposed to RS4X virus at a nominal multiplicity ofnot shown) and supported efficiently the growth of the
rev-defective genome, RS4X (Fig. 1). infection (m.o.i.) of 0.15, washed, then 5 1 105 cells were
harvested immediately and after 48 hr. Total cellular RNATo initiate propagation of rev-defective virus, cells of
the CEMrev1 line were transfected with the proviral mu- was isolated using RNAzolB (Tel-Test, Inc., Friendswood,
TX). Viral RNA was measured using two cDNA-PCRtant pRS4X using cationic liposomes as described pre-
viously (6). As the transfected cells were maintained in assays. When a primer pair corresponding to sequences
culture, exponential viral propagation yielded 0.1 mg/ml
of p24 antigen and caused typical cytopathic effects (Fig.
TABLE 11A and data not shown). However, the rev-defective RS4X
virus did not grow as rapidly as the wild type in these CEM cells CEMrev1 cellsp24
Virus antigencells. Nucleotide sequence analysis of the RS4X virus
stocka (pg/ml) TCID50/ml pg/TCID50 TCID50/ml pg/TCID50produced revealed preservation of all four mutations
(data not shown). Viral replication was not detected when
NL43 1.7 1 106 5.0 1 104 34 1.6 1 105 11
RS4X virus was used to inoculate parental CEM cells; RS4X 3.0 1 106 0 NMb 1.6 1 105 19
RSNS 7.1 1 106 0 NMb 1.5 1 104 450however, this virus remained able to replicate in CEM-
rev1 cells (Fig. 1B). a Virus stocks were produced by transfection of CEMrev1 cells and
The infectious titers of the rev-defective and wild-type then passage of the produced viruses once in CEMrev1 cells. These
viral stocks obtained from the CEMrev1 cultures were stocks were used subsequently for high-multiplicity infections.
b NM, not measurable.determined by terminal dilution using both CEM and
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in exons 1 and 5 was used to detect the presence of any
spliced viral mRNA, cells infected with RS4X virus were
indistinguishable from cells infected with wild-type virus
(Fig. 2). However, when a primer pair corresponding to
sequences in exons 1 and 5E was used to detect the
Rev-dependent mRNA that expresses Vpu and Env, the
signal from cells infected with RS4X virus was diminished
greatly compared to that from cells infected with wild-
type virus (Fig. 2). This inability to direct the accumulation
of incompletely spliced mRNAs confirmed the rev-defec-
tive phenotype of the RS4X virus (1).
The rev-defective RS4X virus was expected to express
the early viral gene products Tat and Nef from rev-inde-
pendent, spliced mRNAs. To detect expression of Nef by
Western blot, CEM cells were infected with RS4X virus
FIG. 3. Expression of the early gene product Nef in CEM cells afteras described above for the RNA assays and harvested
infection with NL43 or RS4X virus at an m.o.i. of 0.15. Cells were har-after 48 hr. Lysates of 105 cells were resolved in a 4%
vested 48 hr postinfection and analyzed by Western blot. Lysates of
stacking, 12% resolving SDS–polyacrylamide gel, blot- approximately 1 1 105 cells were resolved in a 12% polyacrylamide,
ted, and probed with a sheep antiserum raised to recom- SDS gel and electroblotted to a nitrocellulose membrane. The mem-
brane was incubated with sheep aNefNL43 antiserum and detectionbinant NefNL43 produced by Escherichia coli. Detection
was performed as described in the text. Numbers to the left indicatewas performed using a donkey anti-sheep IgG conjugate
molecular weights in kilodaltons; the arrowhead indicates 27 kDa Nef.(The Binding Site, San Diego, CA) and enhanced chemilu-
M, low molecular weight biotinylated marker (Bio-Rad, Richmond, CA);
minescence (Amersham International, Arlington Heights, lane 1, uninfected CEM cells; lane 2, cells infected with NL43; lane 3,
IL). Cells infected with RS4X virus accumulated Nef pro- cells infected with RS4X; lane 4, cell line CEM4B, which expresses Nef
constitutively from a rev-defective provirus (16).tein, although to a lesser extent than cells infected with
wild-type virus (Fig. 3); this difference may have been
due to secondary infection by wild-type virus within the
48 hr following inoculation of the cultures. Interestingly,
analysis of surface CD4-expression by flow cytometry
failed to reveal CD4-downregulation in cells exposed to
the rev-defective virus (data not shown), even though this
virus expressed detectable Nef protein. However, even
after exposure to a similar inoculum of wild-type virus,
CD4-downregulation was detected in only 5% of cells
and was not observed until 72 hr after infection (data
not shown). The inability to detect CD4-downregulation
induced by the rev-defective virus likely resulted from an
insufficient multiplicity of infection.
Defective viruses such as the rev-defective RS4X might
be able to use the wild type as a helper virus and propa-
gate during mixed infection. To test this possibility, CEM
cells were exposed to a mixture of the defective and the
wild-type viruses. A 10:1 ratio of defective to wild-typeFIG. 2. Expression of viral RNA in parental CEM cells after infection
virus was used based on the nominal titer of each viralwith NL43 or RS4X virus at a nominal m.o.i. of 0.15. CEM cells (5 1
105) were harvested immediately after exposure to virus (postwash) stock. Both the rev-defective RS4X virus and the rev-
and after 48 hr. Cellular RNA was analyzed by cDNA-PCR. Primers and nef-defective RSNS virus were tested in these mixed
located in exons 1 and 5 were used to detect multiply spliced RNA infections with the wild-type. After exposure to the viral
species (lanes 1–5), and primers located in exon 1 and 5E were used
mixtures, the infected cells were washed and then main-to detect the bicistronic RNA that expresses vpu and env (lanes 6–
tained in culture for 10 days. The production of p24 anti-10). 10% of the PCR products were resolved on a 6%, nondenaturing,
acrylamide gel, transferred to a nylon membrane, and hybridized with gen by cultures infected with these viral mixtures was
a [g-32P]ATP-labeled oligonucleotide probe specific for exon 5 as pre- identical to that of cultures inoculated only with wild-type
viously described (4, 7). Lanes 1 and 6, uninfected; lanes 2 and 7, NL43 virus (data not shown); there was no evidence of viral
post-wash; lanes 3 and 8, RS4X postwash; lanes 4 and 9, NL43 48 hr
interference by either of the rev-defective viruses. To de-postinfection; lanes 5 and 10, RS4X 48 hr postinfection. The 1/5 and
termine if the defective viruses had used the wild-type1/5E exon junctions are contained in the PCR products indicated by
the arrows and were determined previously (7). as a helper virus during mixed infection, virions har-
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petent virus. The rev-defective virus produced by this
system was able to direct the accumulation of early viral
gene products including spliced viral mRNAs and Nef
protein. Late gene products such as incompletely spliced
viral mRNAs and p24gag antigen were not expressed.
Thus, these viral stocks may potentially be used to study
early events during viral replication such as viral entry,
uncoating, and proviral DNA formation in the absence of
expression of late viral genes or secondary infection.
During mixed infection with the wild type, these rev-de-
FIG. 4. Production of virions containing rev-defective genomes during fective viruses did not modulate the net production of
mixed infection with the wild type. Culture supernatants harvested 10 p24 antigen but were produced at low levels, presumably
days after infection of CEM cells with either a mixture of defective and using the wild type as a helper virus.
wild-type viruses, wild-type virus alone, or defective virus alone were
Conceivably, rev-defective viruses similar to those de-analyzed by cDNA-PCR and hybridization for the presence of rev-defec-
scribed here might be developed as gene transfer vec-tive genomic RNA. The amplicon used contains the second coding
exon of rev; the primers are described in the text. Upper, 2% agarose tors targeted to CD4-positive cells. The nef gene has
gel of the cDNA-PCR products stained with ethidium bromide. Lower, been used as a convenient site for the insertion of heter-
Autoradiogram of the PCR products after blotting to a nylon membrane ologous sequences into HIV-1 (8). In this regard, the con-
and hybridization with [g-32P]ATP-labeled oligonucleotide probe
tribution of nef to the infectivity of these defective virusesSC4951, specific for the mutated rev sequence encoding termination
as shown here is likely to be important to the efficiencycodons at positions 49 and 51. M, FX-174 HaeIII digest (604 bp frag-
ment); lane 1, mixture of RS4X (m.o.i. of 0.15) with NL43 (m.o.i. of 0.015); of gene transfer by this or any HIV-based vector system.
lane 2, NL43 only (m.o.i. of 0.015); lane 3, RS4X only (m.o.i. of 0.15); One potential use of an HIV-derived vector is the transfer
lane 4, mixture of RSNS (m.o.i. of 0.016) with NL43 (m.o.i. of 0.0016); of antiviral genes into susceptible host cells. A theoreti-
lane 5, NL43 only (m.o.i. of 0.0016); lane 6, RSNS only (m.o.i. of 0.016);
cal attribute of an HIV-based vector for gene therapy islane 7, control cDNA-PCR amplification containing no target RNA.
the potential for spread using the wild type as a helper
virus. This ability to use the wild type as a helper virus
is shown here in the case of rev-defective HIV-1. Anothervested after 10 days of culture were analyzed for the
presence of the mutated rev-sequence using cDNA-PCR potential use of an HIV-based vector system is the ex-
pression of immunogenic viral gene products. The majorfollowed by detection using an allele-specific oligonucle-
otide probe. Virion-associated RNA was extracted using immunogenic viral gene product that is suitable for ex-
pression by rev-defective HIV-1 is Nef. Cytotoxic lympho-RNAzolB from 50 ml of culture supernatants containing
1–2 mg/ml of p24 antigen, and cDNA-PCR was performed cyte (CTL) responses directed against Nef have been
detected frequently in infected patients (9). CTL re-using primers corresponding to sequences bracketing
the second coding exon of rev (8096NL: 5*GGATGGAGT- sponses against HIV proteins including Nef have also
been detected in uninfected individuals at high risk forGGGACAGAGAAATTAAC3*; RevE2: 5*CTATTCTTTAGT-
TCCTGACTCCAA3*). Hybridization was performed using HIV-exposure (10–12). These findings have led to specu-
lation that these individuals may have acquired a degreean oligonucleotide specific for the sequence encoding
the mutations at codons 49 and 51 of rev (SC4951: of protection from infection as a result of viral exposures
that failed to result in productive infection (12, 13). In5*GAGATAGAGATAGAT3*). This analysis demonstrated
that both the RS4X and RSNS genomes were packaged principle, a rev-defective virus could be developed as a
vaccine strain that would not lead to a productive infec-using the wild type as a helper virus (Fig. 4). The hybrid-
ization signals obtained from the mixed infections were tion. Such a preparation would deliver not only defective
virions but would express intracellularly a subset of viralgreater than the signals obtained from cultures infected
only with the defective viruses (reflecting the background gene products (Tat and Nef). In comparison to live, atten-
uated immunodeficiency viruses (14), rev-defective HIV-signals from the inocula) and the signals obtained from
cultures infected only with the wild-type virus (reflecting 1 would be unable to establish an active infection in the
host and presumably would entail less risk of causingthe background-hybridization to wild-type sequence).
The apparently greater degree of packaging of the rev- disease (15).
defective genome during mixed infection using RS4X vi-
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